Cell Processing Instruments Market Size & Growth Forecast 2027–2036, By Segments (Application, End-use, Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Cell Processing Instruments Market size was worth USD 7.4 billion in 2026 and is expected to grow at a 6.65% CAGR between 2027 and 2036, crossing USD 14.09 billion by 2036. The industry revenue for 2027 is estimated at USD 7.81 billion.
Get more details on this report
Request Free Sample ReportCell Processing Instruments Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 38.39% of the market in 2026, driven by established biopharmaceutical infrastructure, advanced research capabilities, and sustained demand for sophisticated cell processing technologies.
- Asia Pacific is expected to expand at an 8.02% CAGR as laboratories and healthcare facilities invest in advanced biomedical research tools and standardized cell processing capabilities.
Segment Momentum
- Cell Isolation/Separation represented 37.42% of the market in 2026, as it is a foundational workflow required before downstream cell analysis, expansion, and therapeutic processing.
- CROs & CMOs are the fastest-growing end-use segment as more drug developers outsource specialized cell processing and manufacturing, increasing demand for versatile instrument platforms.
Market Expansion Drivers
- Rising clinical trials for cell-based therapies driving demand for advanced cell separation systems.
- Expanding adoption of personalized and regenerative medicine increasing demand for cell processing workflows.
- Increasing automation and robotics integration in cell therapy manufacturing improving scalability.
Leading Market Participants
- Top companies in the cell processing instruments market include Thermo Fisher Scientific Inc. (United States), Danaher Corporation (United States), Merck KGaA (Germany), Sartorius AG (Germany), Becton, Dickinson and Company (United States), Agilent Technologies, Inc. (United States), Bio-Rad Laboratories, Inc. (United States), Miltenyi Biotec B.V. & Co. KG (Germany), Bio-Techne Corporation (United States), Revvity, Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 7.4 billion
- 2027 Estimated Market Size: USD 7.81 billion.
- Projected Market Size: USD 14.09 billion by 2036
- Growth Forecast: 6.65% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Cell Isolation/Separation (Application) | Pharmaceutical & Biotechnology Companies (End-use) | Cell Separator Systems (Type)
- Emerging Opportunity Segment: Cell Viability & Proliferation (Application) | CROs & CMOs (End-use) | Cell Imaging Systems (Type)
Market Growth Drivers and Industry Trends
Rising clinical trials for cell-based therapies driving demand for advanced cell separation systems
The expanding pipeline of cell-based therapies is increasing the need for reliable technologies capable of isolating, separating, concentrating, and preparing cells for research and therapeutic applications, which will drive the cell processing instruments market growth. As clinical investigations advance, researchers and manufacturers require instruments that can process heterogeneous cell populations while maintaining cell viability, purity, and functional characteristics. Advanced separation systems support critical steps such as cell enrichment, depletion of unwanted populations, and preparation of therapeutic cell material, making them increasingly important across translational research and clinical manufacturing workflows. Growing experimentation with different cell types and therapeutic approaches is also creating demand for instruments that can accommodate diverse processing requirements and laboratory protocols.
Expanding adoption of personalized and regenerative medicine increasing demand for cell processing workflows
The shift toward therapies tailored to individual patients is creating greater reliance on specialized cell handling and processing procedures, thereby propelling the cell processing instruments market as personalized and regenerative medicine applications expand. These therapeutic approaches frequently involve the collection, modification, expansion, selection, or preparation of patient-derived or donor-derived cells, requiring controlled workflows that preserve cell quality throughout processing. Instruments supporting washing, separation, concentration, counting, and other processing stages can help laboratories and manufacturing facilities establish reproducible procedures across complex cell-based applications. The increasing focus on using living cells as therapeutic materials is consequently strengthening the need for processing technologies that can accommodate sensitive biological samples while supporting controlled workflow execution.
Increasing automation and robotics integration in cell therapy manufacturing improving scalability
Automation and robotics are becoming increasingly important in cell therapy manufacturing because they can reduce manual intervention and improve consistency across complex processing steps, which will boost cell processing instruments market demand. Automated platforms can coordinate repetitive tasks such as liquid handling, cell transfer, washing, sampling, and process monitoring while reducing variability associated with manual operations. Robotics integration can also support closed or semi-closed workflows, helping manufacturers manage contamination risks and improve process standardization as production requirements become more demanding. Greater automation further enables facilities to document process parameters and integrate instruments into broader manufacturing systems, supporting more consistent execution of cell processing activities across different production stages.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising clinical trials for cell-based therapies driving demand for advanced cell separation systems | 2.10% | High | North America, Europe | High | Near Term |
| Expanding adoption of personalized and regenerative medicine increasing demand for cell processing workflows | 2.00% | High | North America, Asia Pacific | High | Mid Term |
| Increasing automation and robotics integration in cell therapy manufacturing improving scalability | 1.70% | Moderate | North America, Europe | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
In the cell processing instruments market, North America held the largest share at 38.39% in 2026, reflecting its advanced biotechnology ecosystem, extensive cell therapy research, and sophisticated biomanufacturing infrastructure. Strong activity in regenerative medicine and cell-based therapeutic development is generating demand for instruments that enable reliable cell isolation, preparation, expansion, separation, and quality assessment. The region also benefits from established research institutions, specialized laboratory capabilities, and a strong focus on reproducibility and process control. Increasing movement toward automated and scalable cell processing workflows is further supporting adoption as developers seek to improve manufacturing efficiency while maintaining stringent quality requirements.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing region, supported by expanding biotechnology research, increasing investment in biopharmaceutical manufacturing, and rising interest in cell and gene therapies. Improvements in research infrastructure and the development of advanced healthcare facilities are enabling broader adoption of specialized cell processing technologies. Growing efforts to establish domestic biomanufacturing capabilities are also encouraging demand for instruments that can support laboratory research through increasingly sophisticated therapeutic production workflows. In addition, the region's expanding scientific talent base and increasing emphasis on precision medicine create favorable conditions for continued investment in cell processing equipment and automation.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Precision Manufacturing FocusGermany emphasizes high-precision cell processing instruments that integrate with standardized bioprocessing workflows. Research institutes and biopharmaceutical manufacturers in Germany increasingly seek automated platforms that enhance quality control and regulatory compliance.
France 🇫🇷
Clinical Research IntegrationFrance is reinforcing the use of cell processing instruments across academic hospitals and translational research centers. End users in France emphasize systems that simplify workflow validation while supporting advanced cellular therapy development.
Italy 🇮🇹
Laboratory Modernization DriveItaly is upgrading laboratory infrastructure with cell processing instruments that improve operational consistency and workflow efficiency. Healthcare and research organizations in Italy increasingly invest in equipment that supports compliant cellular processing activities.
Japan 🇯🇵
Regenerative Medicine AlignmentJapan supports demand for advanced cell processing instruments through continued investment in regenerative medicine. Laboratories and manufacturers in Japan prioritize compact, reliable technologies that enable consistent handling of sensitive cellular materials.
South Korea 🇰🇷
Bioprocess Expansion SupportSouth Korea is strengthening demand for cell processing instruments as domestic biopharmaceutical manufacturing capabilities expand. Companies in South Korea focus on flexible automated equipment that supports efficient clinical and commercial-scale cell production.
United States 🇺🇸
Advanced Cell Therapy InfrastructureThe U.S. continues expanding cell processing instrument adoption through increasing clinical manufacturing capacity and automation requirements. Organizations in the U.S. prioritize scalable, GMP-compliant systems that improve reproducibility for cell and gene therapy production.
Segment Leadership and Growth Trends
Cell Processing Instruments Market Share (%), by Application, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportApplication Segment Analysis: Cell Isolation/Separation (Largest Segment) vs Cell Viability & Proliferation (Fastest-Growing Segment)
The cell processing instruments market was dominated by the cell isolation/separation segment, which held a 37.42% share in 2026. Cell isolation and separation are foundational steps in research and bioprocessing because they enable the extraction and preparation of specific cell populations for downstream analysis, therapeutic development, and manufacturing workflows. Growing activity in cell-based research and regenerative medicine is increasing the need for efficient and reproducible separation techniques. Advances in automated processing, improved sample purity, and the need to handle complex biological materials are further supporting adoption of instruments designed for consistent cell isolation.
Cell viability & proliferation is the fastest-growing application segment, driven by the increasing importance of assessing cell health, growth, and functional characteristics during research and therapeutic development. Reliable viability and proliferation measurements are essential for evaluating cell behavior, optimizing culture conditions, and validating experimental outcomes. The expansion of cell-based assays, regenerative medicine research, and advanced biological workflows is creating greater demand for instruments that provide accurate and reproducible measurements. Automation and improved analytical capabilities are also enabling researchers to process samples more efficiently, supporting wider adoption of these applications.
End-use Segment Analysis: Pharmaceutical & Biotechnology Companies (Largest Segment) vs CROs & CMOs (Fastest-Growing Segment)
Pharmaceutical & biotechnology companies represented the largest end-use segment of the cell processing instruments market, accounting for a 43.6% share in 2026. These organizations rely on cell processing technologies across drug discovery, biological research, cell-based assays, and development of advanced therapies. The expanding focus on biologics, personalized medicine, and cell-based approaches is increasing the need for reliable instruments capable of supporting controlled and reproducible cell workflows. Demand is further reinforced by investments in research infrastructure and the growing complexity of biological development programs, which require efficient cell preparation and analysis capabilities.
CROs & CMOs constitute the fastest-growing end-use segment as pharmaceutical and biotechnology organizations increasingly rely on external partners for specialized research, development, testing, and manufacturing activities. Outsourcing allows organizations to access technical expertise, specialized infrastructure, and scalable processing capabilities without maintaining all functions internally. As outsourced biological workflows become more sophisticated, CROs and CMOs require dependable cell processing instruments to support reproducible operations and diverse client requirements. The broader shift toward flexible development models and externalized bioprocessing is therefore strengthening demand within this segment.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Application | Cell Isolation/Separation, Cell Imaging & Counting, Cell Viability & Proliferation, Others | Cell Isolation/Separation | Cell Viability & Proliferation |
| End-use | Pharmaceutical & Biotechnology Companies, CROs & CMOs, Academic & Research Institutes, Others | Pharmaceutical & Biotechnology Companies | CROs & CMOs |
| Type | Cell Counters, Cell Imaging Systems, Flow Cytometers, Cell Separator Systems, Automated Cell Processing Systems, Others | Cell Separator Systems | Cell Imaging Systems |
Competitive Landscape and Market Positioning
Leading companies in the cell processing instruments market:
1. Thermo Fisher Scientific Inc. (United States)
2. Danaher Corporation (United States)
3. Merck KGaA (Germany)
4. Sartorius AG (Germany)
5. Becton Dickinson and Company (United States)
6. Agilent Technologies Inc. (United States)
7. Bio-Rad Laboratories Inc. (United States)
8. Miltenyi Biotec B.V. & Co. KG (Germany)
9. Bio-Techne Corporation (United States)
10. Revvity Inc. (United States)
The cell processing instruments market is advancing through increasing automation in biologics and regenerative medicine workflows. Development efforts focus on improving scalability and precision in cell handling processes. The cell processing instruments market is also influenced by rising demand for standardized and contamination-free processing systems. Innovation is strengthening efficiency across complex therapeutic manufacturing environments.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Danaher Corporation (United States) | |||||||
| Merck KGaA (Germany) | |||||||
| Sartorius AG (Germany) | |||||||
| Becton Dickinson and Company (United States) | |||||||
| Agilent Technologies Inc. (United States) | |||||||
| Bio-Rad Laboratories Inc. (United States) | |||||||
| Miltenyi Biotec B.V. & Co. KG (Germany) | |||||||
| Bio-Techne Corporation (United States) | |||||||
| Revvity Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Danaher, SR-TIGET | Mar-26 | Danaher and SR-TIGET launched the Danaher Beacon collaboration to advance next-generation genomic medicine platforms, focusing on lentiviral gene transfer and targeted gene editing of hematopoietic stem cells. The initiative aims to improve automation and efficiency across cell manipulation workflows, strengthening cell and gene therapy manufacturing capabilities and translational research infrastructure. |
| Alfa Laval | Oct-25 | Alfa Laval launched the Culturefuge 200 B separator designed for medium-scale high-density fermentation and cell harvesting applications. The system utilizes Hermetic Design and Bactofuge technology to enable gentle continuous separation processes, improving efficiency in microbial separation, cell debris removal, and bioprocessing workflows. |
| Bruker Corporation | Jun-25 | Bruker Corporation introduced the timsMetabo platform alongside integration of RECIPE ClinMass kits with the EVOQ DART-TQ+ system for therapeutic drug monitoring. The development enhances analytical capabilities for biomolecular profiling and expands Bruker’s instrumentation portfolio supporting high-precision cell and metabolomics research applications. |
| BD | May-25 | BD launched the FACSDiscover A8 cell analyser integrating spectral cytometry with real-time imaging, enabling profiling of more than 50 cellular parameters per cell. The system enhances high-dimensional cell analysis capabilities, supporting advanced research and translational workflows in cell therapy, immunology, and precision medicine applications. |
| Merck KGaA | Jan-25 | Merck KGaA acquired HUB Organoids to expand its 3D cell culture and next-generation biology portfolio. The acquisition adds organoid model generation, assay development, and high-throughput screening capabilities, strengthening Merck’s position in advanced cell-based research tools and accelerating innovation in drug discovery and regenerative medicine workflows. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Cell Processing Instruments Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Workflow Stage | Cell Preparation, Cell Separation & Isolation, Cell Analysis & Characterization, Cell Expansion & Culture, Cell Harvesting & Formulation |
| Cell Type | Mammalian Cells, Stem Cells, Immune Cells, Primary Cells, Microbial Cells |
| Purchase Model | Direct Capital Purchase, Reagent Rental & Instrument Placement, Leasing, Instrument-as-a-Service |
Cell Processing Instruments Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Cell Therapy Manufacturing Workflow Assessment |
|
| Cell Processing Automation Adoption |
|
| Single-Use Technology Adoption Strategy |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current revenue of the cell processing instruments market?
What are the growth projections for the cell processing instruments industry?
How is the expansion of cell-based therapies influencing investment in cell processing instruments?
Why is automation becoming a strategic priority in the cell processing instruments market?
Why is Cell Isolation/Separation the largest application in the cell processing instruments market?
Which end-use segment is growing the fastest in the cell processing instruments market?
What makes North America the leading regional market for cell processing instruments?
Why is Asia Pacific emerging as the fastest-growing region for the cell processing instruments market?
Which companies are driving growth in the cell processing instruments landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization